Migraine - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：189頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Migraine - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Migraine - Pipeline Review, H1 2014’, provides an overview of the Migraine’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Migraine
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Migraine
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Migraine - Pipeline Review, H1 2014’, provides an overview of the Migraine’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Migraine
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Migraine
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Migraine Overview 9
Therapeutics Development 10
Pipeline Products for Migraine - Overview 10
Pipeline Products for Migraine - Comparative Analysis 11
Migraine - Therapeutics under Development by Companies 12
Migraine - Therapeutics under Investigation by Universities/Institutes 16
Migraine - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Migraine - Products under Development by Companies 21
Migraine - Products under Investigation by Universities/Institutes 24
Migraine - Companies Involved in Therapeutics Development 25
Bristol-Myers Squibb Company 25
Allergan, Inc. 26
Amgen Inc. 27
Eli Lilly and Company 28
Questcor Pharmaceuticals, Inc. 29
BioDelivery Sciences International, Inc. 30
Nektar Therapeutics 31
Merck & Co., Inc. 32
TheraJect, Inc. 33
Biofrontera AG 34
Astellas Pharma Inc. 35
Dr. Reddy's Laboratories Limited 36
Pfizer Inc. 37
Impax Laboratories, Inc. 38
Revance Therapeutics, Inc. 39
IntelGenx Corp. 40
NovaDel Pharma, Inc. 41
Paladin Labs Inc. 42
Transcept Pharmaceuticals, Inc. 43
Pozen, Inc. 44
D-Pharm Ltd. 45
Ache Laboratorios Farmaceuticos S/A 46
Alder Biopharmaceuticals Inc. 47
CoLucid Pharmaceuticals, Inc. 48
Charleston Laboratories, Inc. 49
Pantarhei Bioscience BV 50
Indus Biotech Private Limited 51
NeurAxon, Inc. 52
Noxxon Pharma AG 53
Monosol Rx, LLC 54
Shin Nippon Biomedical Laboratories, Ltd. 55
Winston Pharmaceuticals, Inc. 56
Medestea Research & Production S.p.A. 57
Proreo Pharma AG 58
Heptares Therapeutics Ltd. 59
iCeutica, Inc. 60
Trigemina, Inc. 61
Exodos Life Science Limited 62
Istituto Italiano di Tecnologia 63
Northern Light Pharmaceuticals AB 64
Migraine - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 71
Assessment by Route of Administration 75
Assessment by Molecule Type 78
Drug Profiles 80
dihydroergotamine mesylate - Drug Profile 80
sumatriptan succinate - Drug Profile 83
rizatriptan benzoate - Drug Profile 85
(sumatriptan succinate + naproxen sodium) - Drug Profile 87
(naproxen sodium + naratriptan hydrochloride) - Drug Profile 89
sumatriptan succinate - Drug Profile 90
sumatriptan succinate - Drug Profile 92
sumatriptan succinate - Drug Profile 94
onabotulinumtoxinA - Drug Profile 95
NXN-188 - Drug Profile 97
oxytocin - Drug Profile 99
LY-2951742 - Drug Profile 100
lasmiditan - Drug Profile 101
doxepin hydrochloride - Drug Profile 103
corticotropin - Drug Profile 104
rimegepant - Drug Profile 106
ALD-403 - Drug Profile 108
MK-1602 - Drug Profile 109
AMG-334 - Drug Profile 110
PP-012 - Drug Profile 111
LBR-101 - Drug Profile 112
CLH-1-T - Drug Profile 114
histamine dihydrochloride - Drug Profile 115
BF-1 - Drug Profile 116
E-4 - Drug Profile 117
DP-VPA - Drug Profile 119
PF-05180999 - Drug Profile 121
zolmitriptan - Drug Profile 122
IPX-232 - Drug Profile 123
AMG-333 - Drug Profile 124
nNOS/NET - Drug Profile 125
INDUS-860 - Drug Profile 126
BEMA Triptan - Drug Profile 127
DIS-COM-TRO - Drug Profile 128
NKTR-192 - Drug Profile 129
IC-1209 - Drug Profile 130
IC-1210 - Drug Profile 131
IC-1211 - Drug Profile 132
sumatriptan succinate - Drug Profile 133
rizatriptan benzoate - Drug Profile 134
(rizatriptan benzoate + ondansetron hydrochloride) - Drug Profile 135
Small molecule to Inhibit CGRP for Migraine - Drug Profile 136
Deina - Drug Profile 137
Tribarcina - Drug Profile 138
Prostaglandin E2 Inhibitor Program - Drug Profile 139
MK-8825 - Drug Profile 140
NOX-L-41 - Drug Profile 141
sec butyl propylacetamide - Drug Profile 142
DORA-12 - Drug Profile 143
dihydroergotamine mesylate - Drug Profile 144
URB-937 - Drug Profile 145
Carbonyl Guanidine Derivatives - Drug Profile 146
AA-71 - Drug Profile 147
cloxyquin - Drug Profile 148
IGF-1 - Drug Profile 149
Small Molecules to Inhibit CGRP Receptor for Migraine - Drug Profile 150
rizatriptan benzoate - Drug Profile 151
DFP-02 - Drug Profile 153
ELS-110 - Drug Profile 154
Migraine - Recent Pipeline Updates 155
Migraine - Dormant Projects 171
Migraine - Discontinued Products 176
Migraine - Product Development Milestones 177
Featured News & Press Releases 177
Appendix 184
Methodology 184
Coverage 184
Secondary Research 184
Primary Research 184
Expert Panel Validation 184
Contact Us 185
Disclaimer 185
List of Tables
Number of Products under Development for Migraine, H1 2014 14
Number of Products under Development for Migraine - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Development, H1 2014 23
Comparative Analysis by Unknown Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2014 28
Migraine - Pipeline by Bristol-Myers Squibb Company, H1 2014 29
Migraine - Pipeline by Allergan, Inc., H1 2014 30
Migraine - Pipeline by Amgen Inc., H1 2014 31
Migraine - Pipeline by Eli Lilly and Company, H1 2014 32
Migraine - Pipeline by Questcor Pharmaceuticals, Inc., H1 2014 33
Migraine - Pipeline by BioDelivery Sciences International, Inc., H1 2014 34
Migraine - Pipeline by Nektar Therapeutics, H1 2014 35
Migraine - Pipeline by Merck & Co., Inc., H1 2014 36
Migraine - Pipeline by TheraJect, Inc., H1 2014 37
Migraine - Pipeline by Biofrontera AG, H1 2014 38
Migraine - Pipeline by Astellas Pharma Inc., H1 2014 39
Migraine - Pipeline by Dr. Reddy's Laboratories Limited, H1 2014 40
Migraine - Pipeline by Pfizer Inc., H1 2014 41
Migraine - Pipeline by Impax Laboratories, Inc., H1 2014 42
Migraine - Pipeline by Revance Therapeutics, Inc., H1 2014 43
Migraine - Pipeline by IntelGenx Corp., H1 2014 44
Migraine - Pipeline by NovaDel Pharma, Inc., H1 2014 45
Migraine - Pipeline by Paladin Labs Inc., H1 2014 46
Migraine - Pipeline by Transcept Pharmaceuticals, Inc., H1 2014 47
Migraine - Pipeline by Pozen, Inc., H1 2014 48
Migraine - Pipeline by D-Pharm Ltd., H1 2014 49
Migraine - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014 50
Migraine - Pipeline by Alder Biopharmaceuticals Inc., H1 2014 51
Migraine - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2014 52
Migraine - Pipeline by Charleston Laboratories, Inc., H1 2014 53
Migraine - Pipeline by Pantarhei Bioscience BV, H1 2014 54
Migraine - Pipeline by Indus Biotech Private Limited, H1 2014 55
Migraine - Pipeline by NeurAxon, Inc., H1 2014 56
Migraine - Pipeline by Noxxon Pharma AG, H1 2014 57
Migraine - Pipeline by Monosol Rx, LLC, H1 2014 58
Migraine - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2014 59
Migraine - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 60
Migraine - Pipeline by Medestea Research & Production S.p.A., H1 2014 61
Migraine - Pipeline by Proreo Pharma AG, H1 2014 62
Migraine - Pipeline by Heptares Therapeutics Ltd., H1 2014 63
Migraine - Pipeline by iCeutica, Inc., H1 2014 64
Migraine - Pipeline by Trigemina, Inc., H1 2014 65
Migraine - Pipeline by Exodos Life Science Limited, H1 2014 66
Migraine - Pipeline by Istituto Italiano di Tecnologia, H1 2014 67
Migraine - Pipeline by Northern Light Pharmaceuticals AB, H1 2014 68
Assessment by Monotherapy Products, H1 2014 69
Assessment by Combination Products, H1 2014 70
Number of Products by Stage and Target, H1 2014 73
Number of Products by Stage and Mechanism of Action, H1 2014 77
Number of Products by Stage and Route of Administration, H1 2014 81
Number of Products by Stage and Molecule Type, H1 2014 83
Migraine Therapeutics - Recent Pipeline Updates, H1 2014 159
Migraine - Dormant Projects, H1 2014 175
Migraine - Dormant Projects (Contd..1), H1 2014 176
Migraine - Dormant Projects (Contd..2), H1 2014 177
Migraine - Dormant Projects (Contd..3), H1 2014 178
Migraine - Dormant Projects (Contd..4), H1 2014 179
Migraine - Discontinued Products, H1 2014 180
List of Figures
Number of Products under Development for Migraine, H1 2014 14
Number of Products under Development for Migraine - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Products, H1 2014 23
Assessment by Monotherapy Products, H1 2014 69
Assessment by Combination Products, H1 2014 70
Number of Products by Top 10 Target, H1 2014 71
Number of Products by Stage and Top 10 Target, H1 2014 72
Number of Products by Top 10 Mechanism of Action, H1 2014 75
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 76
Number of Products by Top 10 Route of Administration, H1 2014 79
Number of Products by Stage and Top 10 Route of Administration, H1 2014 80
Number of Products by Top 10 Molecule Type, H1 2014 82
Number of Products by Stage and Top 10 Molecule Type, H1 2014 83
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Migraine Overview 9
Therapeutics Development 10
Pipeline Products for Migraine - Overview 10
Pipeline Products for Migraine - Comparative Analysis 11
Migraine - Therapeutics under Development by Companies 12
Migraine - Therapeutics under Investigation by Universities/Institutes 16
Migraine - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Migraine - Products under Development by Companies 21
Migraine - Products under Investigation by Universities/Institutes 24
Migraine - Companies Involved in Therapeutics Development 25
Bristol-Myers Squibb Company 25
Allergan, Inc. 26
Amgen Inc. 27
Eli Lilly and Company 28
Questcor Pharmaceuticals, Inc. 29
BioDelivery Sciences International, Inc. 30
Nektar Therapeutics 31
Merck & Co., Inc. 32
TheraJect, Inc. 33
Biofrontera AG 34
Astellas Pharma Inc. 35
Dr. Reddy's Laboratories Limited 36
Pfizer Inc. 37
Impax Laboratories, Inc. 38
Revance Therapeutics, Inc. 39
IntelGenx Corp. 40
NovaDel Pharma, Inc. 41
Paladin Labs Inc. 42
Transcept Pharmaceuticals, Inc. 43
Pozen, Inc. 44
D-Pharm Ltd. 45
Ache Laboratorios Farmaceuticos S/A 46
Alder Biopharmaceuticals Inc. 47
CoLucid Pharmaceuticals, Inc. 48
Charleston Laboratories, Inc. 49
Pantarhei Bioscience BV 50
Indus Biotech Private Limited 51
NeurAxon, Inc. 52
Noxxon Pharma AG 53
Monosol Rx, LLC 54
Shin Nippon Biomedical Laboratories, Ltd. 55
Winston Pharmaceuticals, Inc. 56
Medestea Research & Production S.p.A. 57
Proreo Pharma AG 58
Heptares Therapeutics Ltd. 59
iCeutica, Inc. 60
Trigemina, Inc. 61
Exodos Life Science Limited 62
Istituto Italiano di Tecnologia 63
Northern Light Pharmaceuticals AB 64
Migraine - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 71
Assessment by Route of Administration 75
Assessment by Molecule Type 78
Drug Profiles 80
dihydroergotamine mesylate - Drug Profile 80
sumatriptan succinate - Drug Profile 83
rizatriptan benzoate - Drug Profile 85
(sumatriptan succinate + naproxen sodium) - Drug Profile 87
(naproxen sodium + naratriptan hydrochloride) - Drug Profile 89
sumatriptan succinate - Drug Profile 90
sumatriptan succinate - Drug Profile 92
sumatriptan succinate - Drug Profile 94
onabotulinumtoxinA - Drug Profile 95
NXN-188 - Drug Profile 97
oxytocin - Drug Profile 99
LY-2951742 - Drug Profile 100
lasmiditan - Drug Profile 101
doxepin hydrochloride - Drug Profile 103
corticotropin - Drug Profile 104
rimegepant - Drug Profile 106
ALD-403 - Drug Profile 108
MK-1602 - Drug Profile 109
AMG-334 - Drug Profile 110
PP-012 - Drug Profile 111
LBR-101 - Drug Profile 112
CLH-1-T - Drug Profile 114
histamine dihydrochloride - Drug Profile 115
BF-1 - Drug Profile 116
E-4 - Drug Profile 117
DP-VPA - Drug Profile 119
PF-05180999 - Drug Profile 121
zolmitriptan - Drug Profile 122
IPX-232 - Drug Profile 123
AMG-333 - Drug Profile 124
nNOS/NET - Drug Profile 125
INDUS-860 - Drug Profile 126
BEMA Triptan - Drug Profile 127
DIS-COM-TRO - Drug Profile 128
NKTR-192 - Drug Profile 129
IC-1209 - Drug Profile 130
IC-1210 - Drug Profile 131
IC-1211 - Drug Profile 132
sumatriptan succinate - Drug Profile 133
rizatriptan benzoate - Drug Profile 134
(rizatriptan benzoate + ondansetron hydrochloride) - Drug Profile 135
Small molecule to Inhibit CGRP for Migraine - Drug Profile 136
Deina - Drug Profile 137
Tribarcina - Drug Profile 138
Prostaglandin E2 Inhibitor Program - Drug Profile 139
MK-8825 - Drug Profile 140
NOX-L-41 - Drug Profile 141
sec butyl propylacetamide - Drug Profile 142
DORA-12 - Drug Profile 143
dihydroergotamine mesylate - Drug Profile 144
URB-937 - Drug Profile 145
Carbonyl Guanidine Derivatives - Drug Profile 146
AA-71 - Drug Profile 147
cloxyquin - Drug Profile 148
IGF-1 - Drug Profile 149
Small Molecules to Inhibit CGRP Receptor for Migraine - Drug Profile 150
rizatriptan benzoate - Drug Profile 151
DFP-02 - Drug Profile 153
ELS-110 - Drug Profile 154
Migraine - Recent Pipeline Updates 155
Migraine - Dormant Projects 171
Migraine - Discontinued Products 176
Migraine - Product Development Milestones 177
Featured News & Press Releases 177
Appendix 184
Methodology 184
Coverage 184
Secondary Research 184
Primary Research 184
Expert Panel Validation 184
Contact Us 185
Disclaimer 185
List of Tables
Number of Products under Development for Migraine, H1 2014 14
Number of Products under Development for Migraine - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Development, H1 2014 23
Comparative Analysis by Unknown Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2014 28
Migraine - Pipeline by Bristol-Myers Squibb Company, H1 2014 29
Migraine - Pipeline by Allergan, Inc., H1 2014 30
Migraine - Pipeline by Amgen Inc., H1 2014 31
Migraine - Pipeline by Eli Lilly and Company, H1 2014 32
Migraine - Pipeline by Questcor Pharmaceuticals, Inc., H1 2014 33
Migraine - Pipeline by BioDelivery Sciences International, Inc., H1 2014 34
Migraine - Pipeline by Nektar Therapeutics, H1 2014 35
Migraine - Pipeline by Merck & Co., Inc., H1 2014 36
Migraine - Pipeline by TheraJect, Inc., H1 2014 37
Migraine - Pipeline by Biofrontera AG, H1 2014 38
Migraine - Pipeline by Astellas Pharma Inc., H1 2014 39
Migraine - Pipeline by Dr. Reddy's Laboratories Limited, H1 2014 40
Migraine - Pipeline by Pfizer Inc., H1 2014 41
Migraine - Pipeline by Impax Laboratories, Inc., H1 2014 42
Migraine - Pipeline by Revance Therapeutics, Inc., H1 2014 43
Migraine - Pipeline by IntelGenx Corp., H1 2014 44
Migraine - Pipeline by NovaDel Pharma, Inc., H1 2014 45
Migraine - Pipeline by Paladin Labs Inc., H1 2014 46
Migraine - Pipeline by Transcept Pharmaceuticals, Inc., H1 2014 47
Migraine - Pipeline by Pozen, Inc., H1 2014 48
Migraine - Pipeline by D-Pharm Ltd., H1 2014 49
Migraine - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014 50
Migraine - Pipeline by Alder Biopharmaceuticals Inc., H1 2014 51
Migraine - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2014 52
Migraine - Pipeline by Charleston Laboratories, Inc., H1 2014 53
Migraine - Pipeline by Pantarhei Bioscience BV, H1 2014 54
Migraine - Pipeline by Indus Biotech Private Limited, H1 2014 55
Migraine - Pipeline by NeurAxon, Inc., H1 2014 56
Migraine - Pipeline by Noxxon Pharma AG, H1 2014 57
Migraine - Pipeline by Monosol Rx, LLC, H1 2014 58
Migraine - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2014 59
Migraine - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 60
Migraine - Pipeline by Medestea Research & Production S.p.A., H1 2014 61
Migraine - Pipeline by Proreo Pharma AG, H1 2014 62
Migraine - Pipeline by Heptares Therapeutics Ltd., H1 2014 63
Migraine - Pipeline by iCeutica, Inc., H1 2014 64
Migraine - Pipeline by Trigemina, Inc., H1 2014 65
Migraine - Pipeline by Exodos Life Science Limited, H1 2014 66
Migraine - Pipeline by Istituto Italiano di Tecnologia, H1 2014 67
Migraine - Pipeline by Northern Light Pharmaceuticals AB, H1 2014 68
Assessment by Monotherapy Products, H1 2014 69
Assessment by Combination Products, H1 2014 70
Number of Products by Stage and Target, H1 2014 73
Number of Products by Stage and Mechanism of Action, H1 2014 77
Number of Products by Stage and Route of Administration, H1 2014 81
Number of Products by Stage and Molecule Type, H1 2014 83
Migraine Therapeutics - Recent Pipeline Updates, H1 2014 159
Migraine - Dormant Projects, H1 2014 175
Migraine - Dormant Projects (Contd..1), H1 2014 176
Migraine - Dormant Projects (Contd..2), H1 2014 177
Migraine - Dormant Projects (Contd..3), H1 2014 178
Migraine - Dormant Projects (Contd..4), H1 2014 179
Migraine - Discontinued Products, H1 2014 180
List of Figures
Number of Products under Development for Migraine, H1 2014 14
Number of Products under Development for Migraine - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Late Stage Development, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Products, H1 2014 23
Assessment by Monotherapy Products, H1 2014 69
Assessment by Combination Products, H1 2014 70
Number of Products by Top 10 Target, H1 2014 71
Number of Products by Stage and Top 10 Target, H1 2014 72
Number of Products by Top 10 Mechanism of Action, H1 2014 75
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 76
Number of Products by Top 10 Route of Administration, H1 2014 79
Number of Products by Stage and Top 10 Route of Administration, H1 2014 80
Number of Products by Top 10 Molecule Type, H1 2014 82
Number of Products by Stage and Top 10 Molecule Type, H1 2014 83
